Clinical Trial Update: Ph I Dasatinib + Erlotinib in Recurrent MG [Phase 1]

View source ↗

Summary

Duke University conducted a Phase 1 trial evaluating the combination of dasatinib and erlotinib in recurrent malignant glioma, including glioblastoma and gliosa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• DASATINIB (Dasatinib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Duke University | Conditions: Glioblastoma, Gliosarcoma | Phase 1 | Status: COMPLETED